AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working

AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years

More From BioPortfolio on "AstraZeneca and Eli Lilly halt late-stage Alzheimer’s study as drug shows no sign of working"